HK Stock Market Move | INNOVENT BIO (01801) is currently up more than 5% with the listing of a reduced version of semaglutide in China. It is expected that the indication for weight reduction with marsetinide will be approved next year.

INNOVENT BIO (01801) is now up more than 5%, rising 5.29% to HK$37.8 at the time of writing, with a trading volume of HK$146 million. On the news front, the world's first GLP-1 receptor agonist for long-term weight management, Nuoheyin, was prescribed for the first time at Zhongshan Hospital affiliated to Shanghai Fudan University. It is reported that on June 25, the National Medical Products Administration (NMPA) approved the marketing application of Nuoheyin in China. On November 17, Nuoheyin announced that the weight-loss version of semaglutide has been officially launched in the domestic market. It is reported that INNOVENT BIO's GLP-1/GCG dual agonist Mazdutide is at the forefront of domestic GLP-1 innovative drugs. Previously, two NDAs for this drug were accepted domestically, with indications including long-term weight management for obese or overweight populations and treatment of type 2 diabetes. The weight-loss indication is expected to be approved in the first half of next year. CICC International believes that INNOVENT BIO's clinical-stage weight-loss drug Mazdutide has the potential to replicate Novo Nordisk's success in Western countries with its blockbuster weight-loss drug.